Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) CFO Michael M. Nolan sold 10,000 shares of the company’s stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $19.76, for a total value of $197,600.00. Following the completion of the transaction, the chief financial officer now directly owns 76,093 shares of the company’s stock, valued at approximately $1,503,598. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

AMRI has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.

Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 4.03% on Thursday, hitting $20.14. The stock had a trading volume of 492,791 shares. Albany Molecular Research has a 52 week low of $9.71 and a 52 week high of $22.30. The stock’s 50-day moving average is $20.09 and its 200-day moving average is $16.97. The company has a market cap of $625.0 million and a P/E ratio of 38.88.

Albany Molecular Research (NASDAQ:AMRI) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.